Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/19736Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Koumarianou, A. | en |
| dc.contributor.author | Fountzilas, G. | en |
| dc.contributor.author | Kosmidis, P. | en |
| dc.contributor.author | Klouvas, G. | en |
| dc.contributor.author | Samantas, E. | en |
| dc.contributor.author | Kalofonos, C. | en |
| dc.contributor.author | Pentheroudakis, G. | en |
| dc.contributor.author | Economopoulos, T. | en |
| dc.contributor.author | Pectasides, D. | en |
| dc.date.accessioned | 2015-11-24T19:01:53Z | - |
| dc.date.available | 2015-11-24T19:01:53Z | - |
| dc.identifier.issn | 1973-9478 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19736 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adenocarcinoma/mortality/pathology/*therapy | en |
| dc.subject | Age Factors | en |
| dc.subject | Aged | en |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | en |
| dc.subject | Carcinoma, Large Cell/mortality/secondary/*therapy | en |
| dc.subject | Carcinoma, Non-Small-Cell Lung/mortality/secondary/*therapy | en |
| dc.subject | Carcinoma, Squamous Cell/mortality/secondary/*therapy | en |
| dc.subject | Chemotherapy, Adjuvant | en |
| dc.subject | Cohort Studies | en |
| dc.subject | Combined Modality Therapy | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Lung Neoplasms/mortality/pathology/*therapy | en |
| dc.subject | Middle Aged | en |
| dc.subject | Neoplasm Staging | en |
| dc.subject | Prognosis | en |
| dc.subject | Radiotherapy, Adjuvant | en |
| dc.subject | Registries | en |
| dc.subject | Survival Rate | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/19933050 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2009 | - |
| heal.abstract | It is controversial whether non-small cell lung cancer (NSCLC) in the elderly constitutes a distinct clinico-biological entity compared to younger counterparts. As reported data are scant and discordant, we sought to analyze retrospectively the medical records of Hellenic NSCLC patients aged >70 years and compare them with those of age (70-45 years) and younger (<45 years) patients. Records were abstracted from the Hellenic Cooperative Oncology Group (HeCOG) cancer registry database. Presentation, management and outcome data of 417 elderly patients aged > or =70, 1374 age 70-45 years old and 115 patients aged < or =45 years old with histologically confirmed NSCLC managed from 1989 until 2004 were retrieved and compared. Elderly patients differed significantly in terms of presence of symptoms (p<0.001), including thoracic pain (p=0.003), dyspnea (p<0.001), cough (p<0.001) and fatigue (p<0.001), eastern Cooperative Oncology Group performance status (PS) 2-3 (p<0.001), and histological type (more commonly diagnosed with squamous cell carcinoma (p<0.002) and less frequently with adenocarcinoma). Although elderly patients had significantly higher rates of PS 2-3, they had significantly better median time to disease progression (TTP) compared to the younger counterpart (6.4 versus 4.3 months p=0.047). Overall survival (OS) was not significantly different between elderly and young patients (median OS 11.8 versus 11.5 months; p=0.6), but platinum-based chemotherapy and radiotherapy were variables associated favorably with TTP and survival in the elderly. This large retrospective series presents strong evidence that NSCLC constitutes a similar clinicopathologic entity in elderly and young individuals with discretely differing biological behavior and that elderly symptomatic patients should be considered for effective anticancer treatment whenever possible. | en |
| heal.journalName | J Chemother | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
